GEN Exclusives

More »

GEN News Highlights

More »
Apr 13, 2010

GSK Taps Activiomics to Research Inflammatory Signaling Mechanisms

  • GlaxoSmithKline has signed on Activiomics to investigate inflammatory signaling mechanisms. The firm was spun out of Barts and The London School of Medicine and Dentistry at Queen Mary University of London based on the development of a mass spectrometry method to analyze and interpret cell-signaling pathways.

    The deal, which marks the first commercial agreement for Activiomics, was inked through GSK’s Respiratory Centre of Excellence for Drug Discovery. Activiomics reports that its Tiquas (targeted in-depth quantification of cell signaling) is quantitative, antibody-free, label-free, and applicable to any cell or tissue sample. This is of significant benefit in the drug development cycle, aiding clinical trial candidate selection and biomarker discovery, thereby reducing development times.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Block That Microbiome Metaphor!

Which way of thinking about the microbiome would best integrate the virome’s contributions?